Cardinal Health Inc (CAH) raises EPS guidance despite a 4% revenue decline, driven by robust pharmaceutical segment ...

Q2 2025 Management View CEO Jason Hollar emphasized strong Q2 performance driven by robust demand in Pharmaceutical and ...

Mizuho Securities analyst Steven Valiquette has reiterated their bullish stance on CAH stock, giving a Buy rating yesterday.Invest with ...

Cardinal Health warned Thursday that if President Donald Trump follows through with threatened tariffs next month, higher ...

Cardinal Health (NYSE:CAH – Get Free Report) had its target price hoisted by equities researchers at Wells Fargo & Company from $127.00 to $135.00 in a research note issued on Wednesday,Benzinga ...

Drug distributor Cardinal Health on Thursday raised its fiscal 2025 adjusted profit forecast as strong demand for costly specialty medicines and branded drugs drove sales at its pharmaceuticals unit.

Citi analyst Daniel Grosslight increased the price target for Cardinal Health (NYSE:CAH) shares to $130 from the previous $129, while keeping a Neutral rating on the stock. The adjustment follows ...

Dublin City Schools has officially backed out of a deal to acquire the vacant Cardinal Health office building, pivoting ...

Leerink raised the firm’s price target on Cardinal Health (CAH) to $156 from $138 and keeps an Outperform rating on the shares. Q2 results ...

Hello, and welcome to the Second Quarter Fiscal Year 2025 Cardinal Health Inc. Earnings Conference Call. My name is George, and I'll be coordinator for today's event. Please note, this conference is ...

Cardinal Health reported an increase in revenue for two of its segments, while the departure of Optimum impacted its Pharmaceuticals segment.

Cardinal Health's pharmaceutical and specialty solutions segment profit increased 7% to $531 million in the second quarter.